Signal Diagnostics (SDx), provides solutions to identify drug sensitive and drug resistant pathogens, using our novel (patent pending) technologies.

SDx has pending patent applications that will change the way scientists detect the presence of DNA and RNA in any sample.  The currently accepted 'gold standard' to perform this type of analysis is termed PCR (or, polymerase chain reaction), the technique has benefited tremendously over the past 15 years from fluorescent chemistries which enable the display of results online and in real-time (known as real-time PCR (RT-PCR)). 

One of the fundamental issues raised with RT-PCR is the requirement for expensive fluorescently labelled target specific probes, either TaqMan, Molecular Beacons, or HybProbes, SDx has developed a rapid and sensitive technique that eliminates the need for such target specific probes with our patent pending technology, Dynamic Flux Amplification (DFA).